Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

A federal judicial panel on Monday ordered that a growing number of lawsuits accusing Novo Nordisk and Eli Lilly of causing ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk finds itself navigating significant operational and market headwinds. The company is intensely focused on maintaining its leadership in the obes ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

The U.S. Food and Drug Administration said on Monday it ‍has granted a national priority voucher to Johnson & Johnson's blood ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...